View Item 

Show simple item record

Repurposing Itraconazole as a Treatment for Advanced Prostate Cancer: A Noncomparative Randomized Phase II Trial in Men With Metastatic Castration‐Resistant Prostate Cancer
dc.contributor.authorAntonarakis, Emmanuel S.
dc.contributor.authorHeath, Elisabeth I.
dc.contributor.authorSmith, David C.
dc.contributor.authorRathkopf, Dana
dc.contributor.authorBlackford, Amanda L.
dc.contributor.authorDanila, Daniel C.
dc.contributor.authorKing, Serina
dc.contributor.authorFrost, Anja
dc.contributor.authorAjiboye, A. Seun
dc.contributor.authorZhao, Ming
dc.contributor.authorMendonca, Janet
dc.contributor.authorKachhap, Sushant K.
dc.contributor.authorRudek, Michelle A.
dc.contributor.authorCarducci, Michael A.
dc.date.accessioned2017-12-15T16:47:05Z
dc.date.available2017-12-15T16:47:05Z
dc.date.issued2013-02
dc.identifier.citationAntonarakis, Emmanuel S.; Heath, Elisabeth I.; Smith, David C.; Rathkopf, Dana; Blackford, Amanda L.; Danila, Daniel C.; King, Serina; Frost, Anja; Ajiboye, A. Seun; Zhao, Ming; Mendonca, Janet; Kachhap, Sushant K.; Rudek, Michelle A.; Carducci, Michael A. (2013). "Repurposing Itraconazole as a Treatment for Advanced Prostate Cancer: A Noncomparative Randomized Phase II Trial in Men With Metastatic Castration‐Resistant Prostate Cancer." The Oncologist 18(2): 163-173.
dc.identifier.issn1083-7159
dc.identifier.issn1549-490X
dc.identifier.urihttps://hdl.handle.net/2027.42/139926
dc.publisherWiley Periodicals, Inc.
dc.publisherAlphaMed Press
dc.subject.otherItraconazole
dc.subject.otherAngiogenesis
dc.subject.otherHedgehog pathway
dc.subject.otherProstate cancer
dc.titleRepurposing Itraconazole as a Treatment for Advanced Prostate Cancer: A Noncomparative Randomized Phase II Trial in Men With Metastatic Castration‐Resistant Prostate Cancer
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelHematology and Oncology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.contributor.affiliationumcUniversity of Michigan, Ann Arbor, Michigan, USA;
dc.contributor.affiliationotherbBarbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA;
dc.contributor.affiliationotherdMemorial Sloan‐Kettering Cancer Center, New York, New York, USA
dc.contributor.affiliationotheraSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA;
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/139926/1/onco0163-sup-0001.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/139926/2/onco0163.pdf
dc.identifier.doi10.1634/theoncologist.2012-314
dc.identifier.sourceThe Oncologist
dc.identifier.citedreferenceTherasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 2000 92 205 – 216
dc.identifier.citedreferenceTannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 2004 351 1502 – 1512
dc.identifier.citedreferenceKantoff PW, Higano CS, Shore ND et al. Sipuleucel‐T immunotherapy for castration‐resistant prostate cancer N Engl J Med 2010 363 411 – 422
dc.identifier.citedreferencede Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration‐resistant prostate cancer progressing after docetaxel treatment: A randomised open‐label trial Lancet 2010 376 1147 – 1154
dc.identifier.citedreferencede Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 2011 364 1995 – 2005
dc.identifier.citedreferenceNilsson S, Franzén L, Parker C et al. Bone‐targeted radium‐223 in symptomatic, hormone‐refractory prostate cancer: A randomised, multicentre, placebo‐controlled phase II study Lancet Oncol 2007 8 587 – 594
dc.identifier.citedreferenceScher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 2012 367 1187 – 1197
dc.identifier.citedreferenceAntonarakis ES, Eisenberger MA Expanding treatment options for metastatic prostate cancer N Engl J Med 2011 364 2055 – 2058
dc.identifier.citedreferenceHanahan D, Weinberg RA Hallmarks of cancer: The next generation Cell 2011 144 646 – 674
dc.identifier.citedreferenceDiMasi JA, Hansen RW, Grabowski HG The price of innovation: New estimates of drug development costs J Health Econ 2003 22 151 – 185
dc.identifier.citedreferenceChong CR, Sullivan DJ Jr New uses for old drugs Nature 2007 448 645 – 646
dc.identifier.citedreferenceKluetz PG, Figg WD, Dahut WL Angiogenesis inhibitors in the treatment of prostate cancer Expert Opin Pharmacother 2010 11 233 – 247
dc.identifier.citedreferenceChong CR, Xu J, Lu J et al. Inhibition of angiogenesis by the antifungal drug itraconazole ACS Chem Biol 2007 2 263 – 270
dc.identifier.citedreferenceAftab BT, Dobromilskaya I, Liu JO et al. Itraconazole inhibits angiogenesis and tumor growth in non‐small cell lung cancer Cancer Res 2011 71 6764 – 6772
dc.identifier.citedreferenceXu J, Dang Y, Ren YR et al. Cholesterol trafficking is required for mTOR activation in endothelial cells Proc Natl Acad Sci U S A 2010 107 4764 – 4769
dc.identifier.citedreferenceKarhadkar SS, Bova GS, Abdallah N et al. Hedgehog signaling in prostate regeneration, neoplasia and metastasis Nature 2004 431 707 – 712
dc.identifier.citedreferenceKim J, Tang JY, Gong R et al. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth Cancer Cell 2010 17 388 – 399
dc.identifier.citedreferenceJanssen‐Ortho, Inc Itraconazole prescribing information, 2001 Accessed December 12, 2012. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020083s040s041s044lbl.pdf.
dc.identifier.citedreferencePili R, Häggman M, Stadler WM et al. Phase II randomized, double‐blind, placebo‐controlled study of tasquinimod in men with minimally symptomatic metastatic castrate‐resistant prostate cancer J Clin Oncol 2011 29 4022 – 4028
dc.identifier.citedreferenceTzelepi V, Karlou M, Wen S et al. Expression of Hedgehog pathway components in prostate carcinoma microenvironment: Shifting the balance towards autocrine signaling Histopathology 2011 58 1037 – 1047
dc.identifier.citedreferenceScher HI, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group J Clin Oncol 2008 26 1148 – 1159
dc.identifier.citedreferenceMorris MJ, Basch EM, Wilding G et al. Department of Defense prostate cancer clinical trials consortium: A new instrument for prostate cancer clinical research Clin Genitourin Cancer 2009 7 51 – 57
dc.identifier.citedreferenceShaffer DR, Leversha MA, Danila DC et al. Circulating tumor cell analysis in patients with progressive castration‐resistant prostate cancer Clin Cancer Res 2007 13 2023 – 2029
dc.identifier.citedreferenceSeifert AW, Zheng Z, Ormerod BK et al. Sonic hedgehog controls growth of external genitalia by regulating cell cycle kinetics Nat Commun 2010 1 1 – 9
dc.identifier.citedreferenceCarducci MA, Saad F, Abrahamsson PA et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone‐refractory prostate cancer Cancer 2007 110 1959 – 1966
dc.identifier.citedreferenceLoRusso PM, Rudin CM, Reddy JC et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC‐0449) in patients with refractory, locally advanced or metastatic solid tumors Clin Cancer Res 2011 17 2502 – 2511
dc.identifier.citedreferenceSmith DC, Smith MR, Sweeney C et al. Cabozantinib in patients with advanced prostate cancer: Results of a phase II randomized discontinuation trial J Clin Oncol 2012. [Epub ahead of print].
dc.identifier.citedreferenceTrump DL, Havlin KH, Messing EM et al. High‐dose ketoconazole in advanced hormone‐refractory prostate cancer: Endocrinologic and clinical effects J Clin Oncol 1989 7 1093 – 1098
dc.identifier.citedreferenceSmall EJ, Halabi S, Dawson NA et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen‐independent prostate cancer patients: A phase III trial (CALGB 9583) J Clin Oncol 2004 22 1025 – 1033
dc.identifier.citedreferenceCarmeliet P, Jain RK Molecular mechanisms and clinical applications of angiogenesis Nature 2011 473 298 – 307
dc.identifier.citedreferenceYu EM, Jain M, Aragon‐Ching JB Angiogenesis inhibitors in prostate cancer therapy Discov Med 2010 10 521 – 530
dc.identifier.citedreferenceTomaschitz A, Pilz S, Ritz E et al. Aldosterone and arterial hypertension Nat Rev Endocrinol 2010 6 83 – 93
dc.identifier.citedreferenceAttard G, Reid AH, Yap TA et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration‐resistant prostate cancer commonly remains hormone driven J Clin Oncol 2008 26 4563 – 4571
dc.identifier.citedreferenceBolland MJ, Bagg W, Thomas MG et al. Cushing’s syndrome due to interaction between corticosteroids and itraconazole Ann Pharmacother 2004 38 46 – 49
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
onco0163-sup-0001.pdf
Size:
1001.KB
Format:
PDF
View/Open
Name:
onco0163.pdf
Size:
1.215MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.